Curevac has reported second interim analysis results from the global Phase IIb/III HERALD study, where its Covid-19 vaccine candidate, CVnCoV, failed to meet prespecified statistical success criteria.

Data showed that CVnCoV had an interim vaccine efficacy of 47% against Covid-19 of any severity.

CVnCoV is a non-chemically modified messenger ribonucleic acid (mRNA), which encodes the prefusion stabilised full-length spike protein of SARS-CoV-2. It is formulated within lipid nanoparticles.

The trial, which was carried out in partnership with Bayer, enrolled nearly 40,000 subjects in ten countries across Latin America and Europe.

About 134 Covid-19 cases that occurred at least two weeks from the second dose administration were included in the second interim analysis.

Initial analyses of the trial indicate age and strain-dependent efficacy of the vaccine, and the data has been shared with the European Medicines Agency (EMA).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A favourable safety profile of the vaccine was confirmed by the Data Safety Monitoring Board (DSMB).

The trial is underway to conduct the final analysis in the coming weeks and the complete data will be evaluated to determine the most suitable regulatory pathway, CureVac noted.

CureVac CEO Dr Franz-Werner Haas said: “While we were hoping for a stronger interim outcome, we recognise that demonstrating high efficacy in this unprecedented broad diversity of variants is challenging.

“As we are continuing toward the final analysis with a minimum of 80 additional cases, the overall vaccine efficacy may change.”

In December last year, CureVac initiated a Phase III clinical study of CVnCoV in healthcare workers at the University Medical Center Mainz, Germany.

Apart from CVnCoV, CureVac is developing second-generation Covid-19 vaccine candidates in collaboration with GlaxoSmithKline (GSK).

CureVac and GSK anticipate advancing the second-generation vaccine candidate into the clinic in the third quarter of this year.

The companies intend to launch the vaccine next year on obtaining the necessary regulatory approval.